Headquartered in 70 St. Mary Axe, London Fiscal year ends December NYSE: CLVT clarivate.com
Clarivate Plc (NYSE: CLVT) provides enriched data, insights and analytics, workflow solutions and expert services. Following the October 6, 2026 divestiture of its Life Sciences & Healthcare segment, the company operates in two segments.
- Academia & Government serves research institutions, libraries and government customers.
- Intellectual Property serves patent, trademark and IP professionals.
Revenue comes primarily from subscriptions, supplemented by re-occurring revenue tied to IP volumes and a shrinking transactional business. The company is shifting customers toward higher-margin subscription products and investing in AI-led innovation across both segments. It is pursuing a Value Creation Plan focused on organic growth, free cash flow expansion and debt reduction. Updated
A sixth straight EPS beat lands alongside revenue that missed expectations, because the Life Sciences and Healthcare divestiture closed October 6 for $488.4 million in net cash, leaving a smaller, subscription-led company behind.
Most investors have never heard of Clarivate. The company operates largely outside mainstream investor attention. While the market fixates on AI darlings trading at triple-digit multiples, this London-based data intelligence company sits…
In the past week or so, a biotech and an energy infrastructure giant saw some huge insider buying. These were not the only notable purchases though.
Clarivate Plc (NYSE: CLVT) provides enriched data, insights and analytics, workflow solutions and expert services.
24/7 Wall St.'s 12-month price target for CLVT is $3.00, rated Buy. The Wall Street consensus target is $2.97. CLVT price prediction →
